Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098349 | 0.80 | HTR1B (0.30) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL2096515 | 0.79 | CNR1 (0.30) | — | |
| SCHEMBL5842368 | 0.78 | CYP2A6 (0.45) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL9572751 | 0.78 | CYP2A6 (0.35) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL2090417 | 0.78 | CYP2A6 (0.38) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL9572752 | 0.78 | CYP2A6 (0.44) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL2091528 | 0.77 | — | — | |
| SCHEMBL28658077 | 0.75 | KDM4E (0.35) | ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL5538538 | 0.74 | CYP2A6 (0.34) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL5538547 | 0.74 | CNR1 (0.41) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102471303-B | Chromene compounds | TOKUYAMA CORP. (JP) | 2016-01-20 | — | — | CN | disclosed |
| EP-2669277-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2684886-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2015-06-03 | — | — | EP | disclosed |
| EP-2669278-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2015-05-27 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8778236-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8709308-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20140054520-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140034884-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20140030529-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-01-30 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6723859-B2 | BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES | TOKUYAMA CORPORATION (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20040014995-A1 | Chromene compounds | KAWABATA YUICHIRO (JP) | 2004-01-22 | — | — | US | disclosed |
| US-20030096117-A1 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1184379-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014995-A1 | Chromene compounds | SMARCE1, SMARCB1, SMARCA2 | ALDH1A1 2905/4885CYP2A6 2241/4885HSD17B10 958/4885 |
| US-20140030529-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | ALDH1A1 1884/4885CYP2A6 1919/4885HSD17B10 871/4885 |
| US-20030096117-A1 | Chromene compound | SMARCE1, SMARCD2, SMARCB1 | ALDH1A1 3101/4885CYP2A6 2342/4885HSD17B10 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.